dog standing in a back yard

Fast Relief Loved By Itchy Dogs
The #1 Prescribed Oral Medication for Allergic Itch in Dogs1

Prescribed for Over 15 Million Dogs and Counting2

Apoquel quickly stops allergic itch right at the source.3

All dogs itch sometimes, but when you notice it happening more and more, it could be a sign of a medical condition.

  • Starts relieving itch in as little as 4 hours.4,5,*
  • #1 prescribed oral product for allergic itch.1
  • Available as a tasty chewable that can be given with or without food.6

*Based on a model study for flea allergic dermatitis.

Petcare Rewards logo

Control Allergic Itch & Earn Up To $80 in Rewards

Join our free pet health Rewards program. Spend your Rewards on products and services at the vet!

IMPORTANT SAFETY INFORMATION: See full Prescribing Information. Do not use Apoquel or Apoquel Chewable in dogs less than 12 months of age or those with serious infections. Apoquel and Apoquel Chewable may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. New neoplastic conditions (benign and malignant) were observed in clinical studies and post-approval. Apoquel and Apoquel Chewable have not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporines. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. Apoquel and Apoquel Chewable have been used safely with many common medications including parasiticides, antibiotics and vaccines.

INDICATIONS: Control of pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

References:

  1. Kynetec - PetTrak, US Pruritus Factored National. Dec. 2023 MAT Canine Pruritus, Total Unique Patients on Apoquel. Zoetis Inc.

  2. Kynetec PetTrak - GAH-284: Unique Patient Count Since Launch Custom Report: Apoquel: January 2014 - February 2024.

  3. Gonzales AJ, Bowman JW, Fici GJ, et al. Oclacitinib (APOQUEL(®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. Journal of Veterinary Pharmacology and Therapeutics. 2014;37(4):317-324. doi:10.1111/vp.12101.

  4. Gadeyne C, Little P, King VL, Edwards N, Davis K, Stegemann MR. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol. 2014;25(6):512-518,e86. doi:10.1111/vde.12166

  5. Data on file: Study Report No. A162R-US-21-C32

  6. Data on File, Study No. 7562W-60-07-690, Zoetis Inc.

APQ-00679R13